Investment Pitches

Pitch Summary:
Atlassian, an Australian enterprise software company, is renowned for its team collaboration tools, led by its flagship product, Jira. Jira is a robust workflow-management platform that streamlines project coordination for development, design and marketing teams. Serving more than 300,000 customers through cloud-based and on-premise solutions, the company is strategically prioritizing cloud migration. Atlassian's growth strategy targets three progressively larger market segments: its core software developer base (23 million potential users), broader technology teams (100 million), and eventually, the global population of knowledge workers (1 billion). The past few years have been challenging, with revenue growth slowing from more than 30% to the low 20% range due to macroeconomic pressures that dampened customer acquisitions and seat expansion. Higher R&D and sales expenses during Atlassian's cloud migration has further weighed on margins, leading to significant multiple compression amid a broader tech sector selloff. However, Atlassian's recent quarterly results signal a potential turnaround. This quarter, the company reported 21% revenue growth, with its cloud segment—66% of total revenue—surging by 31%. That outperformed consensus growth of 27%, marking its largest beat since introducing cloud-specific guidance. Non-GAAP operating margins reached 23%, surpassing the 19% estimate, while management raised fiscal year 2025 revenue guidance modestly. Stable paid-user expansion among existing enterprise customers for the second consecutive quarter may also suggest a bottoming in this segment. Atlassian's share price increased about 60% during the fourth quarter of 2024, ending a difficult year on a strong note. We remain focused on the company's compelling long-term opportunity. Atlassian's low-cost, open-architecture and user-friendly collaboration tools deliver measurable cost savings and productivity gains for clients. With a strong market position and a serviceable addressable market of nearly $70 billion—compared to current sales of approximately $4.4 billion—Atlassian has the potential for sustained double-digit growth.

BSD Analysis:
Brown Capital Management presents a compelling bull case for Atlassian following a strong turnaround quarter that demonstrated the company's resilience after a challenging period. The manager highlights Atlassian's impressive Q4 results, with 21% revenue growth and cloud segment growth of 31% that beat consensus expectations by 400 basis points. The company's cloud migration strategy is paying dividends, with cloud now representing 66% of total revenue and operating margins expanding to 23% versus 19% estimates. Management's ability to stabilize enterprise customer expansion for two consecutive quarters suggests the business has found its footing after macro headwinds. The investment thesis centers on Atlassian's massive addressable market opportunity of $70 billion compared to current sales of $4.4 billion, providing substantial runway for sustained double-digit growth. The manager emphasizes the company's competitive advantages through low-cost, user-friendly collaboration tools that create meaningful switching costs and deliver measurable productivity gains for clients. With the stock up 60% in Q4 after significant multiple compression, Brown Capital views this as validation of their long-term conviction in the company's market position and growth potential.

Pitch Summary:
UnitedHealth is the largest player in Medicare Advantage and, accordingly, had a disappointing year. Fortunately, the company's diverse business mix mitigated the headwinds. By contrast, the second-largest provider, Humana, is a pure play and has suffered greatly. Two years ago, consensus earnings expectations for 2026 were more than $40. Today, consensus EPS has declined to below $15. Humana is a problematic stock for many investors to own. Earnings may decline from 2025 to 2026 due to mechanical lags in Medicare reimbursement and poor Star Ratings results. Despite this subdued near term, it may be one of the most attractive stocks in the market. Based on our forecast, it has a 10-year forward earnings yield of 30-45%. Eagle established a position last year.

BSD Analysis:
Eagle Capital views Humana as a contrarian opportunity despite significant near-term challenges in the Medicare Advantage market. The company's pure-play exposure to Medicare Advantage has created severe earnings pressure, with consensus 2026 EPS estimates falling from over $40 to below $15 in just two years. Mechanical lags in Medicare reimbursement and poor Star Ratings results will likely cause earnings to decline from 2025 to 2026, making it unattractive to many investors. However, Eagle sees this pessimism as creating exceptional long-term value, with their analysis suggesting a 30-45% 10-year forward earnings yield. The dramatic earnings reset and market abandonment have created what Eagle believes may be one of the market's most attractive opportunities. Eagle's willingness to establish a position during maximum pessimism demonstrates their conviction in the long-term recovery potential. The investment thesis relies on Medicare Advantage market normalization and Humana's ability to navigate regulatory challenges while maintaining its market position.

Pitch Summary:
UnitedHealth is the firm's longest-standing position. We have continuously held it since 1999. It is up more than a hundredfold. This year, we expect it to generate more than five dollars of earnings for every dollar of Eagle's initial purchase price—a truly long-term P/E of less than 0.2x. Investments like this are rare. Three conditions typically need to be in place. First, it must be a great business. Second, it must participate in a large market and continue to capture new growth opportunities. Finally, there must be enough enduring controversies and concerns that the valuation never becomes overpriced. The last couple of years illustrate the occasional difficulties the managed care industry faces. A combination of cyclical pressures, regulatory change, and headline risk has caused significant earnings pressure and multiple compression. The most dramatic downturn has been in Medicare Advantage, a historically fast-growing and attractive market. UnitedHealth is the largest player in Medicare Advantage and, accordingly, had a disappointing year. Fortunately, the company's diverse business mix mitigated the headwinds.

BSD Analysis:
Eagle Capital's 25-year investment in UnitedHealth represents one of their most successful long-term holdings, delivering over 100x returns since 1999. The company exemplifies Eagle's ideal investment criteria: exceptional business quality, participation in large addressable markets, and persistent valuation discounts due to ongoing controversies. UnitedHealth's current earnings power generates over $5 for every dollar of Eagle's original investment, creating an effective P/E ratio below 0.2x on the initial cost basis. The company's diversified business model across UnitedHealthcare and Optum segments provides resilience during cyclical downturns in specific areas like Medicare Advantage. Recent headwinds from regulatory changes and cyclical pressures in Medicare Advantage have created temporary earnings pressure but haven't undermined the long-term thesis. Eagle views these periodic challenges as features rather than bugs, keeping valuations reasonable and preventing overpricing. The managed care industry's structural growth drivers and UnitedHealth's market leadership position support continued long-term value creation despite near-term volatility.

Pitch Summary:
Amazon and ConocoPhillips can coexist in a concentrated portfolio because we are agnostic in building our collection of long-term absolute return streams. ConocoPhillips offers a current earnings yield that is approaching double digits. It meets our return goals with modest growth, which we believe it will deliver. The first category reflects companies with high starting free cash flow yields and modest growth. Partnering with good capital allocators is crucial because the management team will allocate so much of the company's market cap over our investment horizon. Investments like AerCap, Comcast, ConocoPhillips, and Shell fit here.

BSD Analysis:
Eagle Capital views ConocoPhillips as an attractive value investment offering near double-digit current earnings yields with modest but reliable growth prospects. The company fits into Eagle's high free cash flow yield category, where strong current returns compensate for lower growth expectations. Management's capital allocation capabilities are particularly important given the significant cash flows the company generates relative to its market capitalization. ConocoPhillips represents a contrasting investment approach to Amazon within the same portfolio, demonstrating Eagle's agnostic stance toward building absolute return streams. The energy company's ability to meet Eagle's return objectives through current yield rather than growth makes it an attractive complement to higher-growth positions. The investment thesis relies on management's proven ability to allocate capital effectively in a cyclical industry. Eagle's confidence in modest growth delivery suggests the company has sustainable competitive advantages in oil and gas exploration and production.

Pitch Summary:
Amazon was a new position for the firm in 2014. At the time, it was the most expensive stock in Eagle's portfolio based on current earnings. In hindsight, it was our cheapest stock on long-term earnings power, trading at a 10-year forward yield of 40%. Using the current year multiple that is widely available to anyone does not predict whether a stock offers value. Instead, it is critical to form a differentiated view of the long-term earnings power of the business. Amazon and ConocoPhillips can coexist in a concentrated portfolio because we are agnostic in building our collection of long-term absolute return streams. Amazon begins at a much lower yield, but we have confidence in its ability to drive high earnings growth over the next decade.

BSD Analysis:
Eagle Capital maintains a bullish stance on Amazon based on its exceptional long-term earnings power despite appearing expensive on current metrics. The fund's 2014 investment thesis proved prescient, as Amazon delivered a 40% 10-year forward earnings yield despite being the portfolio's most expensive stock at the time. Eagle emphasizes that traditional valuation metrics fail to capture Amazon's true value proposition, requiring a differentiated view of long-term earnings potential. The company fits into Eagle's framework as a growth compounder with significant runway for earnings expansion over the next decade. Amazon's ability to reinvest capital at high returns and expand into new markets supports the fund's confidence in sustained high earnings growth. The position demonstrates Eagle's willingness to pay higher current multiples for businesses with exceptional long-term compounding potential. This investment exemplifies the fund's philosophy of focusing on absolute return streams rather than traditional value metrics.

Pitch Summary:
MonotaRO is a Japan-based e-commerce platform for Maintenance, Repair and Operations (MRO) products for small, medium and enterprise customers. MRO covers a wide range of products, from gloves to cutting tools to nuts and bolts. The MRO market in Japan is estimated at 10 trillion yen (approximately $70 billion USD), with roughly 80% of orders still processed offline, including fax and face-to-face transactions. MonotaRO offers 659,000 SKUs with same-day shipment, out of a total catalog of about 22.9 million. The breadth of the catalog helps meet clients' needs in long-tail items that may not be otherwise available offline. The company also saves time and money for its clients through efficient matching and delivery, and transparent pricing across all channels and customers. This quarter, MonotaRO announced strong second quarter results with 13% year-over-year sales growth and 20% operating profit growth. This was driven by a combination of nearly 30% growth in the enterprise business segment, where MonotaRO is expanding its wallet share and successfully passing through price increases from inflation. We remain confident about MonotaRO's leading position in the online MRO space and its solid execution.

BSD Analysis:
Brown Capital Management views MonotaRO as a dominant e-commerce platform disrupting Japan's massive $70 billion MRO market, which remains 80% offline through antiquated fax and face-to-face transactions. The company's comprehensive catalog of 22.9 million SKUs, with 659,000 available for same-day shipment, addresses the long-tail needs of small, medium, and enterprise customers seeking specialized maintenance and repair products. MonotaRO's value proposition centers on operational efficiency, transparent pricing, and superior product availability compared to traditional offline channels. Strong Q2 performance demonstrated the company's execution capabilities with 13% sales growth and impressive 20% operating profit expansion. The enterprise segment's nearly 30% growth highlights MonotaRO's success in expanding wallet share and implementing price increases amid inflationary pressures. The manager emphasizes the significant digitization opportunity in Japan's fragmented MRO market, where MonotaRO's scale advantages and logistics capabilities create sustainable competitive moats. The company's ability to serve both routine and specialized product needs positions it well for continued market share gains in the digital transformation of industrial procurement.

Pitch Summary:
MercadoLibre is a Uruguay-based company that operates the leading e-commerce shopping platform in Latin America (like Amazon) and provides payment and credit services (like PayPal). Although Latin America is a large market with a population of 650 million, it still has low e-commerce penetration compared to most developed markets as well as China. We first bought MercadoLibre in our International Small Company portfolio in 2013 and graduated the holding to the International All Company in 2020. Currently, about half of MercadoLibre's business is in Brazil and a quarter of it is in Argentina. Long-term investments in the marketplace and its rapid-shipping solutions provide significant barriers to entry for competitors. MercadoLibre ships 50% of its orders with same-day and next-day shipping to nearly 57 million buyers. We also like the potential in the company's newer fintech businesses, where 52 million unique users benefit from MercadoLibre's payment-processing services, credit cards, loans and savings accounts. In the quarter, MercadoLibre reported 42% year-over-year revenue growth and 9% EBIT growth (both in USD terms). Items sold, the key metric to strip out foreign-exchange and inflation noise, grew 30% year over year, accelerating to the highest level since the second quarter of 2021. In fintech, the company grew monthly active users 37% year over year, while non-performing loan trends remained stable. We believe that MercadoLibre's e-commerce and fintech ecosystem provides a unique competitive advantage. The company accumulates so-called first-party (1P) data on transactions from its marketplace. This consumer data informs the company's underwriting, creating a robust funnel for cross-selling its suite of consumer or merchant-facing payment and credit services. This should support sustained market share gains in fintech going forward, in our view.

BSD Analysis:
Brown Capital Management positions MercadoLibre as a dominant e-commerce and fintech platform capitalizing on Latin America's underpenetrated digital economy. The Uruguay-based company operates the leading marketplace serving 650 million people across Latin America, with significant growth runway given low e-commerce penetration versus developed markets. MercadoLibre's dual-platform strategy combines Amazon-like e-commerce with PayPal-style financial services, creating powerful network effects and cross-selling opportunities. The company's logistics investments have established formidable competitive moats, with 50% of orders delivered same-day or next-day to 57 million buyers. Strong Q3 performance included 42% revenue growth and accelerating 30% growth in items sold, reaching the highest level since Q2 2021. The fintech ecosystem shows exceptional momentum with 37% growth in monthly active users to 52 million, while maintaining stable credit quality. Brown Capital emphasizes the strategic value of first-party transaction data enabling superior underwriting and cross-selling across payment and credit services. The manager's conviction is demonstrated through an 11-year holding period and successful graduation from Small Company to All Company portfolios in 2020.

Pitch Summary:
The third tranche is larger companies that have found a second (or third, or fourth) growth curve. The best example of that in the portfolio today is Novo Nordisk, the Denmark-based, global pharmaceutical company. Although its insulin business has matured, this EGC has found tremendous growth in obesity care, as discussed in the Detractors section below. Novo Nordisk is a Denmark-based, global pharmaceutical company focused on diabetes and obesity, which comprise 93% of the company's revenue. We have owned the company since 2013 and believe the company typifies an EGC, as it is dominant and innovative, and doing something that is mission-critical in a large and growing global market. Being one of the most significant players in diabetes care gives Novo Nordisk the focus and resources necessary to develop new treatments related to metabolic health. The key to the company's recent growth, however, is the new medicines in the glucagon-like peptide-1 (GLP-1) class of therapies that essentially mimic a hormone that lets the brain know when one has had enough to eat. Novo Nordisk is the global market leader in the GLP-1 segment, with a 55% market share and the blockbuster obesity-care drug Wegovy. Wegovy delays gastric emptying (the time it takes for food to leave the stomach), contributing to a feeling of satiety. GLP-1 drugs are showing promise of promoting overall health. The obesity market alone reached $24 billion in 2023, according to iQVIA, more than seven times the estimated market size just three years ago. Furthermore, the obesity market is now forecasted to reach $131 billion by 2028. Novo Nordisk reported results for the first half of 2024 of 25% sales growth and 19% operating profit growth (at constant foreign exchange rates), including 37% sales growth and 1.5 percentage points of market share gain in obesity care. Management revised its sales outlook to 22% to 28% growth from 19% to 27% previously. Despite these numbers, the results fell short of market expectations, hurting the share price. Of particular concern to investors are supply challenges and net pricing pressures, particularly from Medicaid, which comprises a growing share of Novo's U.S. business, now covering 10 million patients for Wegovy. The September Senate hearing on pricing for Ozempic and Wegovy added to the uncertainty. Additionally, Novo's $1 billion acquisition in 2023 of Monlunabant, an oral weight-loss drug, released disappointing phase 2a clinical-trial data. Nevertheless, we remain confident in Novo Nordisk's market potential and its continued focus on ensuring supply to help as many patients as possible address the obesity challenge.

BSD Analysis:
Brown Capital Management views Novo Nordisk as the quintessential example of their third investment tranche - large companies discovering new growth curves beyond their mature core businesses. The Danish pharmaceutical giant exemplifies their Exceptional Growth Company approach, having successfully transitioned from a mature insulin franchise to dominating the revolutionary GLP-1 obesity market. With 55% market share in GLP-1 therapies and blockbuster drug Wegovy, Novo Nordisk has captured a massive growth opportunity in a market expanding from $24 billion in 2023 to a projected $131 billion by 2028. The company's strong operational performance includes 25% sales growth and 37% obesity care growth in H1 2024, demonstrating successful execution of their obesity strategy. Despite near-term headwinds including supply constraints, Medicaid pricing pressures, and regulatory scrutiny, Brown Capital maintains conviction in the long-term structural growth opportunity. The manager's 11-year holding period since 2013 reflects deep conviction in management's ability to navigate challenges while capitalizing on the obesity epidemic. Novo Nordisk's dominant market position and innovative pipeline provide sustainable competitive advantages in the rapidly expanding metabolic health market.

Pitch Summary:
One example of such a company in the International All Company portfolio is Monday.com, an Israel-headquartered, cloud-based workflow-management solutions provider. Monday IPO-ed in June 2021 and its revenue exceeded $500 million by the end of the next year. It has generated significant positive free cash flow since 2023, when we first purchased it, and the company finally achieved positive GAAP earnings in the second quarter of 2024.

BSD Analysis:
Brown Capital Management positions Monday.com as a representative example of their second investment tranche - early-stage growth companies with revenue exceeding $500 million that are ineligible for their Small Company portfolio. The Israeli workflow management software provider demonstrates the evolving IPO landscape where companies go public later in their lifecycles and take longer to reach profitability. Monday.com's rapid revenue growth trajectory, reaching over $500 million within a year of its June 2021 IPO, showcases strong market demand for cloud-based workflow solutions. The company's progression to positive free cash flow generation since 2023 and achievement of GAAP profitability in Q2 2024 validates Brown Capital's investment timing and thesis. The manager's initial purchase in 2023 coincided with the company's inflection point toward cash flow positivity. Monday.com represents the opportunity set of later-stage IPOs that still offer significant growth potential. The SaaS business model provides recurring revenue visibility and scalability advantages in the competitive workflow management space.

Pitch Summary:
A good example is REA, the Australian real estate portal that allows real estate agents to match sellers with potential buyers. We first bought REA in the International Small Company portfolio at its inception in 2013 and added it to the International All Company strategy in 2020. At that time, we thought that REA fit the International All Company portfolio based on its industry and business model. In addition, we verified that REA had sufficient shares available for trading (by looking at float and average daily trading volume, among other things) so that we could build and exit a position without unduly affecting share prices. Finally, there's capacity. Brown Capital does not want to own too high a percentage of a company's total shares outstanding. Today, REA's market capitalization is around 28 billion AUD (or $19 billion USD) so we can have quite sizable positions in REA in both portfolios without owning too much of the company from a risk-management point of view.

BSD Analysis:
Brown Capital Management views REA Group as a prime example of their portfolio construction strategy, holding the Australian real estate portal in both their International Small Company and International All Company strategies. The manager emphasizes REA's strong business model as a digital marketplace connecting real estate agents with buyers and sellers. The company's substantial market capitalization of approximately $19 billion USD provides sufficient liquidity and capacity for meaningful position sizes across multiple portfolios. REA represents a successful graduation story, having been initially purchased in the Small Company portfolio in 2013 before being added to the All Company strategy in 2020. The manager's confidence is demonstrated through their willingness to maintain significant exposure across multiple strategies. The digital real estate platform benefits from network effects and market leadership in the Australian property market. Brown Capital's long-term holding period reflects their conviction in REA's durable competitive advantages and growth prospects.

Pitch Summary:
In industrials, we trimmed Illinois Tool Works and initiated a position in a similar high-quality diversified industrial franchise, Parker-Hannifin, a motion and control technologies company with growing aerospace and defense exposure currently representing about 40% of the business. While both companies are high-quality diversified industrial franchises, the latter has been able to grow faster by pivoting toward a longer-cycle A&D business, yet its stock continues to trade at a discount relative to its peers.

BSD Analysis:
The manager initiated Parker-Hannifin as a replacement for Illinois Tool Works, viewing both as high-quality diversified industrial franchises but preferring Parker-Hannifin's superior growth profile. The company's motion and control technologies business benefits from significant aerospace and defense exposure, representing approximately 40% of operations and providing longer-cycle, more predictable revenue streams. This strategic pivot toward A&D markets has enabled faster growth compared to traditional industrial peers while maintaining the defensive characteristics of diversified industrial operations. Despite this superior growth trajectory and strategic positioning, the stock continues trading at a discount to peer valuations, creating an attractive entry opportunity. The manager values the combination of high-quality franchise characteristics, accelerated growth through A&D exposure, and relative valuation discount. The longer-cycle nature of aerospace and defense contracts provides more visibility and stability compared to shorter-cycle industrial end markets, supporting sustainable growth and margin expansion over time.

Pitch Summary:
In IT, we bought Broadcom as we believe the company has a long runway for growth with its custom silicon business, which should be more durable and less volatile than other components within the AI food chain. We also believe the acquisition of VMware creates another opportunity for steady, subscription-based durable growth that is still in its early innings. We believe the stock has an attractive risk/reward profile given the reasonable visibility toward mid-teens EPS growth at a low-20s P/E multiple.

BSD Analysis:
The manager initiated a position in Broadcom, attracted by the company's differentiated positioning within the AI ecosystem through its custom silicon business. Unlike other AI-related components, Broadcom's custom silicon offering is viewed as more durable and less volatile, providing sustainable competitive advantages. The VMware acquisition adds another growth vector through steady, subscription-based revenue streams that are still in early development stages. The manager sees significant runway for both business segments to drive long-term growth. The investment case is supported by reasonable visibility toward mid-teens EPS growth, which appears attractive when combined with the stock's low-20s P/E multiple valuation. This combination of growth visibility and reasonable valuation creates what the manager views as an attractive risk-reward profile. The dual growth engines of custom silicon and VMware's subscription model provide diversified exposure to technology trends while maintaining more predictable revenue characteristics than typical semiconductor cyclicality.

Pitch Summary:
Starbucks is an iconic global coffee roaster brand with a deep-rooted heritage of communal experience centered around coffee consumption. From the business standpoint, it offers attractive exposure to breakfast/morning food and beverage consumption, which tends to be stickier and more habitual. While the company has been going through a challenging period operationally, we think new CEO Brian Niccol brings enormous credibility supported by a long and successful career that includes impressive turnarounds at Taco Bell and Chipotle. Niccol's operational expertise gives us confidence he can improve the customer experience while restoring business profitability by taking Starbucks to its successful roots. We think the stock offers very good value for what the business is capable of on a normalized basis.

BSD Analysis:
The manager views Starbucks as an iconic global brand with deep-rooted heritage and strong positioning in the sticky breakfast and morning consumption category. Despite recent operational challenges, the appointment of new CEO Brian Niccol provides significant confidence in a successful turnaround. Niccol's proven track record of impressive turnarounds at Taco Bell and Chipotle demonstrates his operational expertise and ability to restore profitability while improving customer experience. The manager believes Niccol can return Starbucks to its successful operational roots, leveraging the brand's inherent strengths in communal coffee experiences. The investment thesis centers on the disconnect between current valuation and the business's normalized earnings potential under improved management. The combination of a world-class brand, defensive consumption characteristics, and proven turnaround leadership creates an attractive risk-reward opportunity. The manager sees significant value creation potential as operational improvements restore the company's historical performance levels.

Pitch Summary:
Skepticism over the consumer has left some high-quality stocks with depressed valuations and allowed us to reduce our consumer discretionary underweight with the addition of O'Reilly Automotive and Starbucks. While we have been cautious on retailers for quite some time, auto parts retailer O'Reilly is a best-in-class, high-quality operator with high returns on invested capital and a solid history of consistent execution and sustainable share gain, and it enjoys rational competitive dynamics in the broader industry. In addition, auto parts retailing carries some counter-cyclicality as consumers tend to hold on to their cars longer, requiring more repair and maintenance, during softer economic environments. We think a high-quality franchise like O'Reilly trading at a reasonable valuation in an otherwise expensive market is worth our attention and we initiated a starter position.

BSD Analysis:
The manager initiated a position in O'Reilly Automotive, capitalizing on consumer skepticism that has created attractive valuations in high-quality retail names. Despite historical caution on retailers, O'Reilly stands out as a best-in-class operator with exceptional returns on invested capital and a proven track record of consistent execution and sustainable market share gains. The company benefits from rational competitive dynamics within the auto parts industry, providing a more stable operating environment than typical retail sectors. The counter-cyclical nature of auto parts retailing offers defensive characteristics, as economic softness typically leads consumers to extend vehicle ownership, driving increased repair and maintenance spending. The manager views the combination of high-quality franchise characteristics and reasonable valuation as compelling in an otherwise expensive market environment. The starter position reflects confidence in the long-term investment merits while acknowledging the initial cautious approach to retail exposure.

Pitch Summary:
Air Products and Chemicals (APD) has also made strong contributions recently, delivering operationally and announcing a major offtake agreement for its NEOM green hydrogen project in June. Strong fundamentals for APD are shining through a soft Chinese industrial economy, and it continues to shore up the strength of its core industrial gases franchise, committing to not invest additional capital on big projects until they soak up existing capacity, putting a management structure in place to allow for more accountability and announcing board-initiated succession planning that will help built investor confidence for the future. The company is also tightening up its operational focus by divesting non-core assets and streamlining operations.

BSD Analysis:
The manager expresses strong confidence in Air Products and Chemicals, highlighting recent operational delivery and strategic progress. The major NEOM green hydrogen offtake agreement represents significant validation of the company's hydrogen strategy and future growth potential. Despite headwinds from a soft Chinese industrial economy, APD's strong fundamentals continue to shine through, demonstrating the resilience of its core industrial gases franchise. Management's disciplined capital allocation approach, including the commitment to absorb existing capacity before new investments, shows prudent financial stewardship. The implementation of enhanced accountability structures and board-initiated succession planning addresses governance concerns and builds investor confidence. The company's operational focus through non-core asset divestitures and streamlined operations positions it for improved efficiency and returns. This combination of strategic progress, operational excellence, and disciplined capital management supports the bullish investment case.

Pitch Summary:
Despite these stock-specific headwinds, we're confident our portfolio continues to own high-quality franchises able to generate excess returns in various economic environments. Sherwin-Williams, for example, has seen its shares rise even while its end markets have not really recovered. As the Fed raised rates aggressively to combat inflation, existing homes turnover came to a halt. Turnover of existing housing stock is Sherwin-Williams's bread and butter business as homeowners typically paint as they are ready to sell and new owners repaint when they buy. Despite slow end market demand and because Sherwin-Williams is a best-in-class operator, it continues to execute well and gain share, taking advantage of some disarray among competitors, allowing it to hold on to pricing and benefit from some raw material deflation.

BSD Analysis:
The manager highlights Sherwin-Williams as an exemplary high-quality franchise capable of generating excess returns across economic cycles. Despite challenging end markets due to halted housing turnover from aggressive Fed rate hikes, the company has demonstrated resilience with rising share prices. The manager emphasizes Sherwin-Williams' best-in-class operational execution, enabling market share gains amid competitor disarray. The company has successfully maintained pricing power while benefiting from raw material cost deflation, showcasing strong margin management. The investment thesis centers on the company's ability to outperform even when its core housing turnover market remains depressed. This operational excellence and competitive positioning are viewed as sustainable advantages that will drive long-term value creation regardless of housing market conditions.

Pitch Summary:
In a similar case of post-COVID market normalization, drug distributor McKesson lowered profit guidance for its medical-surgical business twice during the period, most likely due to continued post-COVID headwinds as primary care sites are consuming less of its equipment, while its prescription technology solution segment is tied to volumes of certain high-value specialty drugs. We still believe McKesson's core pharma distribution business is very healthy, however, and it is ramping up its Optum contract in the second half of the year, while its most recent oncology practices acquisition should be accretive over the long term, enabling McKesson to continue delivering low-double-digit earnings growth without much economic sensitivity.

BSD Analysis:
The manager remains bullish on McKesson despite recent guidance cuts in the medical-surgical segment, attributing weakness to post-COVID normalization rather than structural issues. The core pharmaceutical distribution business is viewed as healthy and resilient. Key growth drivers include the ramping Optum contract in the second half and recent oncology practice acquisitions expected to be accretive long-term. The manager emphasizes McKesson's ability to deliver low-double-digit earnings growth with minimal economic sensitivity, highlighting the defensive characteristics of the pharma distribution model. The temporary headwinds in medical-surgical equipment and specialty drug volumes are seen as cyclical rather than permanent impairments. The investment case rests on the stability and growth potential of the core distribution franchise, supported by strategic contract wins and accretive acquisitions in higher-margin oncology services.

Pitch Summary:
In the information technology (IT) sector, Intel has come under additional pressure due to continued softness in the company's core PC and server markets as well as concerns on the company's longer-term competitive position. While Intel's turnaround is not happening overnight, we are constructive on the outlook into 2025: the company's product positioning should be much improved and it should be positioned to gain market share in a cyclical upswing in which it has strong earnings power. A somewhat adverse spending environment due to AI myopia has weighed on shares, but we still think the market is undershipping PCs and general servers following a COVID normalization period that saw demand get pulled ahead and then languish as companies froze IT budgets. The installed base is now getting older, and we expect a strong refresh cycle into next year. The delay is actually beneficial to Intel, whose product positioning will be all the more improved. While our investment case is not predicated on an M&A transaction, and we believe one is unlikely, the expression of interest in the company speaks to the value of the assets, which we think still trade at a meaningful discount to fair value.

BSD Analysis:
The manager maintains a constructive view on Intel despite near-term headwinds in PC and server markets. The investment thesis centers on an anticipated cyclical recovery in 2025 driven by an aging installed base requiring refresh cycles. The manager believes Intel's product positioning will significantly improve by next year, positioning the company to gain market share during the expected upturn. Current weakness is attributed to post-COVID demand normalization and AI-related spending shifts rather than fundamental deterioration. The manager views the stock as trading at a meaningful discount to fair value, with the delay in recovery actually benefiting Intel's competitive positioning. While not banking on M&A activity, recent acquisition interest validates the underlying asset value. The pitch reflects confidence in Intel's earnings power during cyclical upswings despite acknowledging the turnaround timeline extends beyond immediate quarters.

Pitch Summary:
Woodward is a mission-critical supplier of components and systems used in the aerospace and industrial sectors. We believe aerospace is one of the most attractive segments of the global economy. The company has a unique growth story within this industry. Design wins have allowed it to triple the dollar value of the components it manufactures for the new generation of narrowbody aircraft—predominantly the Airbus A320neo and the Boeing 737 Max. Narrowbody aircraft are the backbone of commercial aviation, flying most domestic routes as well as shorter international ones. Because it takes decades for the global fleet to turn over, the economic impact of these wins on aftermarket revenue has scarcely begun. These share gains should allow Woodward to outgrow competitors during the next decade and post EPS growth in the mid-to-high-teens. In addition, its earnings mix should improve over time as it becomes more concentrated in the aerospace aftermarket. This may cause investors to give it a premium valuation. Despite this outlook, Woodward trades at a discount to peers at a low 20s multiple of 2025 free cash flow. We estimate that 70% of Woodward's profit next year will come from aerospace and 30% from industrial. Within aerospace, 57% of segment profit comes from commercial aftermarket, 13% from new commercial aircraft, and 30% from defense. Aerospace is an attractive end market. The demand side exhibits growth well above that of the overall economy. From 1970-2020, global passenger traffic grew at a 6% CAGR. This increase was driven by a rising global middle class, the continued buildout of global airport infrastructure, and the expansion of low-cost airlines. Despite this growth, nearly 80% of the world's population has never flown on an airplane. The supply side exhibits strong moats supported by technical differentiation, regulation, and 20-year platform cycles. Components must be certified by the FAA, and leasing companies also have strict mandates. These forces lead to strong pricing power. Woodward supplies critical engine components to both CFM, a joint venture between GE and Safran, and Pratt & Whitney. These products include fuel pumps, fuel metering units, actuators, air valves, fuel nozzles, and thrust reverser actuation systems. In essence, Woodward's components support the nervous system of an airplane, translating pilot inputs into precise mechanical actions and ensuring that all parts work together smoothly. Woodward's products are typically sole-sourced, meaning it is the only company supplying the part once a system is selected for a plane or engine. The company makes modest profits selling the original equipment and higher margins selling replacement parts. Because a given model is sold for two decades, this translates to a more than 40-year aftermarket period over the platform's life, resulting in high predictability and pricing power. Woodward's technical capabilities in engine controls are unmatched. Our diligence indicates that GE tried to insource some of these capabilities but could not match Woodward's technical prowess. Pratt & Whitney uses several Woodward parts even though its sister company, Collins, sells competing ones. Within its industrial segment, Woodward sells into three primary end markets: 1) transportation (marine, natural gas trucks, and off-highway equipment), 2) power generation (natural gas turbines and diesel power systems), and 3) oil & gas. Woodward's tripling of its content share on the new generation of narrowbody aircraft is a unique growth driver versus industry peers. Current financials understate the company's potential earnings power because new generation aftermarket revenue has yet to come in, a dynamic that is about to change. The early A320neo and 737 Max aircraft are just beginning their initial scheduled engine overhauls. Over the next decade, Woodward should durably outgrow its market as older aircraft retire and the fleet transitions to this new generation. Aerospace industry aftermarket revenue should grow high single digits over time, comprised of ~4-5% passenger traffic and 3-4% price. On top of this, Woodward's content gains should contribute another 5%, leading to low double-digit civil aerospace aftermarket growth. This aftermarket revenue growth comes with attractive incremental margins, likely 45% or higher. Compared to aerospace segment margins of ~20% and overall company operating margins of ~15%, this mix shift should lead to significant margin expansion. We expect aerospace segment margins to expand from ~20% to ~28% over the next decade, with overall company margins increasing from ~15% to 23%. There is further margin upside from additional pricing actions, which we believe are a core focus of Woodward's new management team. Over time, we expect aerospace's contribution to Woodward's earnings to increase from 70% to more than 80%, and aftermarket to shift from 57% of aerospace profit to 70%. This increase in aerospace aftermarket exposure should reasonably lead to multiple expansion. The public markets have rewarded commercial aftermarket-focused companies like Transdigm, GE, and Heico with high multiples, which trade at 32x, 32x, and 60x EPS, respectively. Eagle initially invested in Woodward during the early stages of the pandemic. The stock market extrapolated a temporary travel disruption as a permanent situation. Later, the company faced supply-chain disruptions and inflation shocks that pressured its P&L and further pushed out its recovery. These challenges had little impact on our view of its long-term earnings power, enabling Eagle to build our position. Because Woodward is relatively underfollowed, it has occasional stock price dislocations, which can offer good opportunities. For example, the stock declined more than 15% on a soft earnings report in the most recent quarter, and we were able to add more to our investment. With Boeing machinists recently on strike, we would not be surprised to see aftershocks from that disruption. None of this should affect multiyear earnings. Woodward is transitioning from a good business to a great business. It was once a company that, when compared to peers, grew its aerospace business in-line, had more exposure to industrial end markets, had below-average margins, and had correspondingly higher earnings volatility. It deserved to trade at a discount. Looking forward, we expect its aerospace segment to grow at a premium to peers. Industrial end markets will become less relevant, margins will significantly rise, and earnings volatility will decline. It shares commonalities with our investments in Marriott and Hilton as they transitioned from more volatile and capital-intensive businesses to the high-growth, high-margin fee companies they are today. In 2022, Woodward brought on CEO Chip Blankenship, who we believe is an excellent fit. He is well-suited to maximize the company's long-term opportunity, both operationally and financially. He has a successful track record in aerospace and industrial businesses, having spent 24 years at GE and leading its commercial aviation division. Blankenship has meaningfully improved Woodward's operations and commercial execution, particularly around pricing, which had underperformed under prior leadership. He has also driven lean manufacturing practices to reduce unnecessary SKUs and create more consistency in the production process, an emphasis that has yielded strong results. Aerospace segment margins increased by approximately 400 basis points from 2022-2024, and industrial margins increased by more than 800. We expect Blankenship to continue these initiatives, driving further margin upside. He recently told investors, 'We're still in the early innings of this journey. I don't know whether it's inning two or inning three, but we're not at the halfway point, and we're not at the seventh inning stretch by a long shot. We have numerous value streams under transformation.' Over the coming 5-10 years, we believe that Woodward can compound revenue at high single digits with margin expansion, leading to low-teens operating profit growth. The company can use its prodigious free cash flow to repurchase stock, enabling EPS growth in the high teens. Because Woodward trades at a discount to peers and in line with the overall market, valuation risk is limited. The stock's return should roughly track with earnings growth. In the downside case, where the company doesn't execute as well as we expect, strategic buyers may be interested in acquiring it. Just as we are, larger aerospace firms are attracted to Woodward's premium aftermarket growth. Moreover, an acquirer could use its scale to drive higher margins. Investing in Woodward is analogous to owning an expanding set of royalties on global air travel. Cashflow streams with this high level of certainty should rationally be priced at a low discount rate, offering investors a skinnier return for taking less risk. Yet Woodward is priced the opposite.

BSD Analysis:
Eagle Capital presents a compelling bull case for Woodward based on the company's tripling of content share on new-generation narrowbody aircraft (A320neo and 737 Max), positioning it for significant aftermarket revenue growth as these planes enter their maintenance cycles. The fund emphasizes Woodward's sole-source supplier status and technical moats in aerospace engine controls, which provide pricing power and predictable cash flows over 40+ year platform lifecycles. Management expects aerospace segment margins to expand from 20% to 28% over the next decade, driven by higher-margin aftermarket revenue mix and operational improvements under CEO Chip Blankenship. The thesis centers on Woodward's transformation from a cyclical industrial company to a premium aerospace aftermarket business, similar to Eagle's successful investments in Marriott and Hilton. Eagle views the current valuation at low-20s FCF multiple as attractive given the company's growth prospects and margin expansion potential. The fund has been opportunistically adding to the position during temporary market dislocations, viewing short-term disruptions as irrelevant to the long-term earnings power. The investment represents a play on global air travel growth with high cash flow visibility and multiple expansion potential as the business mix shifts toward higher-quality aerospace aftermarket revenues.

Pitch Summary:
EW is a medtech company focused on heart disease. The main segments/products are the Transcatheter Aortic Valve Replacement (TAVR) and the Transcatheter Mitral and Tricuspid Therapies (TMTT). Both are artificial valves to replace malfunctioning ones. The market for TAVR is maturing and EW has a 60/65% market share. Each valve costs around $35k and are the most expensive ones in the market. EW created this market but now they are suffering from competition from Medtronic and Abbot. In Q2 the company revised guidance downwards for this segment (which is 90% of profits) from ~9% to ~6% - ouch. European healthcare systems are more focused on price than the US one, so the lower price point for similar valves is having an impact. I think EW will be a market share loser in Europe and to a lesser extent, in the US. The company blamed the TAVR slowdown on decreased hospital capacity for heart procedures. Which is possible, since I believe the whole TAVR market is growing, but maybe we are just witnessing a normalization of the level of procedures after the Covid backlog. TMTT is another valve for both the tricuspid and the mitral valves (These ones suffer from different issues vs the aortic valve, the main one is when the valves don't close properly, allowing some blood to go back to the auricle). This segment is growing almost triple digits and there are not any other valves in the market. Although not a valve, Abbott has the MitraClip, which consists in "clipping" parts of the valve to facilitate closure. The company has been hit by max pessimism as the multiple has come down to accommodate for HSD growth in TAVR while we wait for TMTT to become a meaningful part of revenues. I think the asymmetry comes from the expansion of the TAVR market led by EW. When new data comes out, we will see if the surgeons start placing these valves for asymptomatic patients that nonetheless have a severe aortic stenosis. Hey, even maybe the management is right and revenues reaccelerate in the US (I doubt Europe can be saved, in more than one sense) at the same time that TMTT becomes are real driver of the share price.

BSD Analysis:
Benedetti presents a contrarian bull case on Edwards Lifesciences despite recent headwinds in the core TAVR business. The manager acknowledges significant challenges including market share losses to Medtronic and Abbott, particularly in price-sensitive European markets, and Q2 guidance cuts from 9% to 6% growth. However, he sees asymmetric upside potential driven by two key catalysts: expansion of the TAVR addressable market through new clinical data supporting treatment of asymptomatic severe aortic stenosis patients, and the rapid triple-digit growth in the TMTT segment where EW maintains monopolistic positioning. The investment thesis hinges on the company's dominant 60-65% TAVR market share and premium $35k valve pricing power, combined with TMTT's potential to become a meaningful revenue driver. Benedetti views current valuation multiples as reflecting maximum pessimism, creating an attractive risk-reward profile. The timing appears opportunistic following the Q2 disappointment that compressed valuations while the underlying structural heart disease market continues expanding.